Yüklüyor......
Cervical cancer – State of the science: From angiogenesis blockade to checkpoint inhibition
Vascular endothelial growth factor (VEGF) has emerged as a therapeutic target in several malignancies, including cervical cancer. Chemotherapy doublets combined with the fully humanized monoclonal antibody, bevacizumab, now constitute first-line therapy for women struggling with recurrent/metastatic...
Kaydedildi:
| Yayımlandı: | Gynecol Oncol |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6720107/ https://ncbi.nlm.nih.gov/pubmed/29666026 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2018.01.009 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|